Sepsis: Rising Cases, Faster Progression & Treatment Challenges

Across Europe, doctors are facing a growing challenge: sepsis is becoming more complex to treat. While sepsis – the body’s overwhelming and life-threatening response to an infection – has always been a serious concern, a confluence of factors is now making it harder to combat. An aging population, the rise of chronic illnesses, and, critically, increasing antimicrobial resistance are reshaping the landscape of this often-fatal condition. Understanding these pressures is vital, as swift diagnosis and treatment remain the cornerstones of survival.

The Shifting Demographics of Sepsis Risk

Sepsis moves quickly. A patient can present with what seems like a common infection and, within hours, develop organ failure. This rapid progression underscores the need for immediate medical intervention. But the patients presenting with sepsis are changing. Europe’s population is aging, and older adults are more vulnerable to infection and its complications. A greater number of people are living with chronic conditions – such as diabetes, heart disease, and kidney disease – which weaken the immune system and increase the risk of developing sepsis. These underlying health issues can also make it harder to recognize sepsis early, as symptoms may be attributed to the existing condition.

Antimicrobial Resistance: A Growing Threat

Perhaps the most significant factor complicating sepsis treatment is antimicrobial resistance (AMR). This occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines designed to kill them. The European Commission highlights that AMR is a major hurdle in treating sepsis, and experts are increasingly concerned that immunotherapy – an approach focused on restoring the body’s own immune function – may turn into less effective in patients with AMR infections.

The rise of AMR isn’t simply a matter of overuse of antibiotics, though that is a contributing factor. Bacteria are remarkably adaptable, and they can develop resistance through genetic mutations and by sharing resistance genes with other bacteria. This means that infections caused by antibiotic-resistant organisms are harder to treat, require longer hospital stays, and are associated with higher mortality rates.

Immunotherapy and the Search for New Approaches

Professor Evangelos Giamarellos-Bourboulis, an infectious-diseases expert at Attikon University Hospital in Athens, has been researching immunotherapy as a potential new way to treat sepsis for the past 18 years. His work, part of the EU-funded ImmunoSep project, focuses on triggering the body’s own immune system to fight off the infection. The core idea is that restoring normal immune function can halt the spread of infection and prevent organ damage. The ImmunoSep trial, coordinated by Professor Mihai G. Netea from Radboud University Nijmegen in the Netherlands, is currently trialling sepsis immunotherapy on patients and is expected to conclude in December 2023.

However, the potential for AMR to undermine immunotherapy is a significant concern. If the pathogens causing the sepsis are resistant to antibiotics, the immune system may struggle to clear the infection even with restored function. This highlights the need for a multi-pronged approach to sepsis treatment, combining immunotherapy with strategies to combat antimicrobial resistance.

The Global Scale of the Problem and European Efforts

Sepsis is a global health crisis. It’s estimated to cause 11 million deaths worldwide each year – almost a fifth of all global deaths. In Europe, the European Sepsis Alliance is working to raise awareness of sepsis and advocate for improved prevention, diagnosis, and treatment. The 2017 WHA 70.7 Sepsis Resolution, passed by the World Health Organization, urges member states to integrate sepsis into their national health systems and strengthen early detection and therapies. The G7 ministers of health and leaders have also committed to fostering the implementation of this resolution, with a focus on synergies with strategies against antimicrobial resistance and infection prevention.

Despite these efforts, integration of sepsis into national health strategies remains incomplete across Europe. The European Sepsis Report notes that only a minority of European countries have fully integrated sepsis into their national health strategies, highlighting the need for continued advocacy and investment.

What Comes Next: Surveillance, Research, and Collaboration

Addressing the growing challenge of sepsis requires a sustained and coordinated effort. Enhanced surveillance systems are crucial for tracking the incidence of sepsis and identifying emerging trends in antimicrobial resistance. Continued research is needed to develop new and more effective treatments, including novel immunotherapies and alternative approaches to combating AMR.

Collaboration between healthcare professionals, researchers, policymakers, and patient advocacy groups is also essential. Sharing data, best practices, and resources can help to accelerate progress and improve outcomes for patients with sepsis. The focus must remain on early recognition, rapid diagnosis, and appropriate treatment, while simultaneously addressing the underlying drivers of antimicrobial resistance and strengthening healthcare systems to cope with the evolving challenges of sepsis.